Staphylococcal Skin and Soft Tissue Infections.


Journal

Infectious disease clinics of North America
ISSN: 1557-9824
Titre abrégé: Infect Dis Clin North Am
Pays: United States
ID NLM: 8804508

Informations de publication

Date de publication:
03 2021
Historique:
pubmed: 12 12 2020
medline: 30 10 2021
entrez: 11 12 2020
Statut: ppublish

Résumé

Staphylococcus aureus is the most common bacteria causing purulent skin and soft tissue infections. Many disease-causing S aureus strains are methicillin resistant; thus, empiric therapy should be given to cover methicillin-resistant S aureus. Bacterial wound cultures are important for characterizing local susceptibility patterns. Definitive antibiotic therapy is warranted, although there are no compelling data demonstrating superiority of any one antibiotic over another. Antibiotic choice is predicated by the infection severity, local susceptibility patterns, and drug-related safety, tolerability, and cost. Response to therapy is expected within the first days; 5 to 7 days of therapy is typically adequate to achieve cure.

Identifiants

pubmed: 33303329
pii: S0891-5520(20)30082-9
doi: 10.1016/j.idc.2020.10.003
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

81-105

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure Dr L.G. Miller has received grants from Merck. Dr T.J. Hatlen has nothing to disclose.

Auteurs

Timothy J Hatlen (TJ)

Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA, USA; Division of HIV, Harbor-UCLA Medical Center, Torrance, CA, USA; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: Timothy.hatlen@lundquist.org.

Loren G Miller (LG)

Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA, USA; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Harbor-UCLA Medical Center, 1000 West Carson Street, Box 466, Torrance, CA 90509, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH